West Windsor, NJ, United States of America

Olafur S Gudmundsson

This inventor holds 6 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2019-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Olafur S Gudmundsson. Retrieved from https://idiyas.com/inventor/olafur-s-gudmundsson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 6 (Patent Applications = 1)

% Patents Active = 100.0

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 7.9

ph-index = 1

Forward Citations = 9(Granted Patents)

Company Filing History:

6 out of 3,745

Bristol-Myers Squibb Compnay

patents

Years Active: 2019-2025

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12478674 - IPILIMUMAB VARIANTS WITH ENHANCED SPECIFICITY FOR BINDING AT LOW PH (2025-11-25),

2. 12097242 - Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides (2024-09-24),

3. 12097241 - Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides (2024-09-24),

4. 11364281 - Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof (2022-06-21),

5. 11185570 - Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides (2021-11-30),

6. 10266578 - Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof (2019-04-23),

Title: Innovations by Olafur S Gudmundsson

Introduction

Olafur S Gudmundsson is a notable inventor based in West Windsor, NJ (US). He has made significant contributions to the field of medical science, particularly in the treatment of kidney failure and cardiovascular conditions. With a total of five patents to his name, his work has the potential to impact many lives.

Latest Patents

His latest patents include innovative methods of treating kidney failure and improving or stabilizing renal function using modified relaxin polypeptides. These modified human relaxin 2 polypeptides comprise a non-naturally encoded amino acid linked to a pharmacokinetic enhancer. The therapeutic uses of these polypeptides extend to treating cardiovascular conditions, such as heart failure, and conditions related to fibrosis.

Career Highlights

Olafur has established a successful career at Bristol-Myers Squibb Company, where he continues to develop groundbreaking treatments. His research focuses on enhancing the efficacy of therapies for serious health conditions, showcasing his commitment to advancing medical science.

Collaborations

He has collaborated with esteemed colleagues, including Gene Michael Dubowchik and Xiaojun Han, to further his research and innovations. These partnerships have contributed to the development of effective therapeutic solutions.

Conclusion

Olafur S Gudmundsson's work exemplifies the spirit of innovation in the medical field. His contributions through patents and collaborations are paving the way for advancements in treatment options for kidney failure and cardiovascular diseases.

Profile summary based on public USPTO records.